Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Tumor-targeting Salmonella typhimurium A1-R prevents experimental human breast cancer bone metastasis in nude mice

Shinji Miwa, Shuya Yano, Yong Zhang, Yasunori Matsumoto, Fuminari Uehara, Mako Yamamoto, Yukihiko Hiroshima, Hiroaki Kimura, Katsuhiro Hayashi, Norio Yamamoto, Michael Bouvet, Hiroyuki Tsuchiya, Robert M. Hoffman _ and Ming Zhao

PDF | HTML | How to cite

Oncotarget. 2014; 5:7119-7125. https://doi.org/10.18632/oncotarget.2226

Metrics: PDF 2035 views | HTML 2543 views | ?

Abstract

Shinji Miwa1,2,3, Shuya Yano1,2, Yong Zhang1,2, Yasunori Matsumoto2, Fuminari Uehara1,2, Mako Yamamoto1,2, Yukihiko Hiroshima1,2, Hiroaki Kimura3, Katsuhiro Hayashi3, Norio Yamamoto3, Michael Bouvet2, Hiroyuki Tsuchiya3, Robert M. Hoffman1,2 and Ming Zhao1

1 AntiCancer, Inc.; San Diego, California USA

2 Department of Surgery; University of California, San Diego; San Diego, California USA

3 Department of Orthopedic Surgery; Kanazawa University Graduate School of Medical Sciences; Kanazawa, Ishikawa, Japan

Correspondence:

Robert M. Hoffman, email:

Keywords: breast cancer, bone metastasis, GFP, RFP, bacterial therapy, Salmonella typhimurium A1-R

Received: July 1, 2014 Accepted: July 16, 2014 Published: July 16, 2014

Abstract

Bone metastasis is a lethal and morbid late stage of breast cancer that is currently treatment resistant. More effective mouse models and treatment are necessary. High bone-metastatic variants of human breast cancer cells were selected in nude mice by cardiac injection. After cardiac injection of a high bone-metastatic variant of breast cancer, all untreated mice had bone metastases compared to only 20% with parental cells. Treatment with tumor-targeting Salmonella typhimurium A1-R completely prevented the appearance of bone metastasis of the high metastatic variant in nude mice (P < 0.001). After injection of the highly bone-metastatic breast cancer variant to the tibia of nude mice, S. typhimurium A1-R treatment significantly reduced tumor growth in the bone (P < 0.001). These data indicated that S. typhimurium A1-R is useful to prevent and inhibit breast cancer bone metastasis and should be of future clinical use for breast cancer in the adjuvant setting.

Creative Commons License

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2226